AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Summary

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Timeline

Start

2023-07-20

Primary completion

2027-08-31

Completion

2028-11-14

Drugs

Indications